• Record cash receipts of $12.0 million, up nearly 50% on prior corresponding period
• Revenue of $9.1 million (unaudited), up over 20% on prior corresponding period
• Danish facility sales into Germany up over 70%

Little Green Pharma Ltd (ASX: LGP) has reported a strong quarter with record cash receipts of $12.0 million, up nearly 50% on the prior corresponding period, and revenue of $9.1 million (unaudited), up over 20% on the prior corresponding period. The increase in cash receipts was driven by $1.0 million of growth in the Health House distribution business and growth in LGP product sale receipts. Revenue was impacted by a decline in Australian budget flower sales, offset by an increase in European flower sales, despite regulatory delays. The company saw a 70% increase in sales from its Danish facility into Germany, as the German market registered record imports of 37.2 tonnes. LGP also launched its first branded products in Germany under the CherryCo line. The company commissioned a new 2.4tpa room at its Danish facility, giving it a total capacity of 8.5tpa, with another 2.4tpa room currently being fitted out. New laws enabling Denmark as a cannabis import, packing and distribution hub will come into effect on 1 January 2026, with preparations underway. The company ended the quarter with $2.5 million in cash and over $5.0 million in unused financing facilities.

For the full year FY25, the company reported revenue of $36.8 million (52% CAGR between FY22-FY25), Adjusted EBITDA of $2.9 million, and Net Profit after Tax of $3.3 million.

The company continues to see rapid growth in the German market, with a record 37.2 tonnes of cannabis imported in CY25Q1, up 15% on the prior quarter. The UK market is also growing rapidly, with the company receiving over $2.0 million in purchase orders for FY26Q2 and Q3.